ID   OV-MZ-5
AC   CVCL_X954
DR   Wikidata; Q54936866
RX   PubMed=1500230;
RX   PubMed=11242531;
RX   PubMed=15153938;
CC   Doubling time: 40 hours (PubMed=1500230).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; None_reported; -; Zygosity=- (PubMed=15153938).
CC   Derived from site: Metastatic; Ascites; UBERON=UBERON_0007795.
DI   NCIt; C7978; Ovarian serous cystadenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   57Y
CA   Cancer cell line
DT   Created: 05-09-14; Last updated: 19-12-24; Version: 9
//
RX   PubMed=1500230; DOI=10.1002/ijc.2910520115;
RA   Mobus V.J., Gerharz C.-D., Press U., Moll R., Beck T., Mellin W.,
RA   Pollow K., Knapstein P.-G., Kreienberg R.;
RT   "Morphological, immunohistochemical and biochemical characterization
RT   of 6 newly established human ovarian carcinoma cell lines.";
RL   Int. J. Cancer 52:76-84(1992).
//
RX   PubMed=11242531; DOI=10.1089/10430340150504019;
RA   Bruning A., Kohler T., Quist S.R., Wang-Gohrke S., Mobus V.J.,
RA   Kreienberg R., Runnebaum I.B.;
RT   "Adenoviral transduction efficiency of ovarian cancer cells can be
RT   limited by loss of integrin beta3 subunit expression and increased by
RT   reconstitution of integrin alphaVbeta3.";
RL   Hum. Gene Ther. 12:391-399(2001).
//
RX   PubMed=15153938; DOI=10.1038/sj.cgt.7700727;
RA   Quist S.R., Wang-Gohrke S., Kohler T., Kreienberg R., Runnebaum I.B.;
RT   "Cooperative effect of adenoviral p53 gene therapy and standard
RT   chemotherapy in ovarian cancer cells independent of the endogenous p53
RT   status.";
RL   Cancer Gene Ther. 11:547-554(2004).
//